Log In or Register to Join The Conversation!
  • This topic is empty.
Viewing 0 reply threads
  • Author
    Posts
    • #14821

      Antisense Therapeutics Announces Positive Results from Phase 2 Study of ATL1102 in DMD

      Australian company Antisense Therapeutics announced encouraging results from its phase 2, open-label clinical trial of the company’s investigational therapy ATL1102 for treating Duchenne muscular dystrophy (DMD). The study met its primary endpoint, which was to assess the safety and tolerability of ATL1102 in patients with DMD who are non-ambulatory (unable to walk independently). After six months of weekly, subcutaneous treatment with a low dose, the drug appeared to be safe and well-tolerated in all participants with only minor side effects. Secondary endpoint results also seemed encouraging, as the drug lowered the average number of specific immune cells during the treatment period and largely improved measurements of functional capacity in seven of nine boys treated.

      What do you think of this news? Do you feel hopeful about this news for DMD?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.
Copyright © 2017-2020 All rights reserved.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account